- About
- Advertise
- CureToday.com
- OncLive.com
- OncNursingNews.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
Catherine S. Diefenbach, MD | Authors
Catherine S. Diefenbach, MD, Talks Future of CAR T-cell Therapy Following Liso-Cel Approval in Second-Line LBCL
July 07, 2022
Catherine S. Diefenbach, MD, spoke about refining understanding of CAR T-cell therapies after the approval of lisocabtagene maraleucel for patients with relapsed/refractory large B-cell lymphoma.
Catherine S. Diefenbach, MD, Discusses Gaps Filled by Approval of Liso-Cel in Second-Line Relapsed/Refractory LBCL
July 01, 2022
Catherine S. Diefenbach, MD, spoke about the approval of lisocabtagene maraleucel for patients with relapsed/refractory large B-cell lymphoma who do not have chemotherapy-sensitive disease.
Catherine S. Diefenbach, MD, Reviews the Approval of Liso-Cel in Second-Line Relapsed/Refractory LBCL
June 29, 2022
Catherine S. Diefenbach, MD, spoke about the approval of lisocabtagene maraleucel for the treatment of relapsed/refractory large B-cell lymphoma following 1 prior therapy.
Checkpoint Inhibition in Hodgkin Lymphoma: Saving the Best for Last?
October 15, 2016
In this article we review the scientific rationale, preclinical evidence, and most recent clinical data for the use of checkpoint inhibitor therapy in patients with relapsed Hodgkin lymphoma.
Peripheral T-Cell Lymphoma: Time for a T-Cell–Centric Standard of Care
September 15, 2013
This is an exciting time in the treatment of PTCL, but with this opportunity comes responsibility. The challenge of how to optimize a plethora of promising new therapies for a small number of patients will drive therapeutic decision making for the foreseeable future.